Guggenheim Maintains Buy on GeneDx Holdings, Lowers Price Target to $70

Benzinga Newsdesk www.benzinga.com Neutral 57.6%

Neg 0% Neu 57.6% Pos 0%

Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $100 to $70.